<?xml version='1.0' encoding='utf-8'?>
<document id="27283486"><sentence text="Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates."><entity charOffset="22-35" id="DDI-PubMed.27283486.s1.e0" text="cyclosporin A" /><entity charOffset="40-52" id="DDI-PubMed.27283486.s1.e1" text="dipyridamole" /><entity charOffset="118-148" id="DDI-PubMed.27283486.s1.e2" text="[(11)C]-N-desmethyl-loperamide" /><pair ddi="false" e1="DDI-PubMed.27283486.s1.e0" e2="DDI-PubMed.27283486.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27283486.s1.e0" e2="DDI-PubMed.27283486.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27283486.s1.e0" e2="DDI-PubMed.27283486.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27283486.s1.e1" e2="DDI-PubMed.27283486.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27283486.s1.e1" e2="DDI-PubMed.27283486.s1.e2" /></sentence><sentence text="Cyclosporin A (CsA) and dipyridamole (DPy) are potent inhibitors of the P-glycoprotein (P-gp; ABCB1) in vitro"><entity charOffset="0-13" id="DDI-PubMed.27283486.s2.e0" text="Cyclosporin A" /><entity charOffset="15-18" id="DDI-PubMed.27283486.s2.e1" text="CsA" /><entity charOffset="24-36" id="DDI-PubMed.27283486.s2.e2" text="dipyridamole" /><pair ddi="false" e1="DDI-PubMed.27283486.s2.e0" e2="DDI-PubMed.27283486.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27283486.s2.e0" e2="DDI-PubMed.27283486.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27283486.s2.e0" e2="DDI-PubMed.27283486.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27283486.s2.e1" e2="DDI-PubMed.27283486.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27283486.s2.e1" e2="DDI-PubMed.27283486.s2.e2" /></sentence><sentence text=" Their efficacy at inhibiting P-gp at the blood-brain barrier (BBB) is difficult to predict" /><sentence text=" Efficient and readily available (i" /><sentence text="e" /><sentence text=" marketed) P-gp inhibitors are needed as probes to investigate the role of P-gp at the human BBB" /><sentence text=" In this study, the P-gp inhibition potency at the BBB of therapeutic doses of CsA or DPy was evaluated in baboons using Positron Emission Tomography (PET) imaging with [(11)C]-N-desmethyl-loperamide ([(11)C]dLop), a radiolabeled P-gp substrate"><entity charOffset="169-199" id="DDI-PubMed.27283486.s7.e0" text="[(11)C]-N-desmethyl-loperamide" /><entity charOffset="201-212" id="DDI-PubMed.27283486.s7.e1" text="[(11)C]dLop" /><entity charOffset="79-89" id="DDI-PubMed.27283486.s7.e2" text="CsA" /><pair ddi="false" e1="DDI-PubMed.27283486.s7.e2" e2="DDI-PubMed.27283486.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27283486.s7.e2" e2="DDI-PubMed.27283486.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27283486.s7.e2" e2="DDI-PubMed.27283486.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27283486.s7.e0" e2="DDI-PubMed.27283486.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27283486.s7.e0" e2="DDI-PubMed.27283486.s7.e1" /></sentence><sentence text=" The preparation of dLop as authentic standard and [(11)C]dLop as radiotracer were revisited so as to improve their production yields" /><sentence text=" [(11)C]dLop PET imaging was performed in the absence (n=3, baseline condition) and the presence of CsA (15mg/kg/h i"><entity charOffset="100-102" id="DDI-PubMed.27283486.s9.e0" text="CsA" /></sentence><sentence text="v" /><sentence text=", n=3)" /><sentence text=" Three animals were injected with i" /><sentence text="v" /><sentence text=" DPy at either 0" /><sentence text="56 or 0" /><sentence text="96 or 2mg/kg (n=1), corresponding to the usual, maximal and twice the maximal dose in patients, respectively, administered immediately before PET" /><sentence text=" [(11)C]dLop brain kinetics as well as [(11)C]dLop kinetics and radiometabolites in arterial plasma were measured to calculate [(11)C]dLop area-under the time-activity curve from 10 to 30min in the brain (AUCbrain) and in plasma (AUCplasma)" /><sentence text=" [(11)C]dLop brain uptake was described by AUCR=AUCbrain/AUCplasma" /><sentence text=" CsA as well as DPy did not measurably influence [(11)C]dLop plasma kinetics and metabolism"><entity charOffset="1-3" id="DDI-PubMed.27283486.s19.e0" text="CsA" /></sentence><sentence text=" Baseline AUCR (0" /><sentence text="85±0" /><sentence text="29) was significantly enhanced in the presence of CsA (AUCR=10"><entity charOffset="50-52" id="DDI-PubMed.27283486.s22.e0" text="CsA" /></sentence><sentence text="8±3" /><sentence text="6)" /><sentence text=" Injection of pharmacologic dose of DPy did not enhance [(11)C]dLop brain distribution with AUCR being 1" /><sentence text="2, 0" /><sentence text="9 and 1" /><sentence text="1 after administration of 0" /><sentence text="56, 0" /><sentence text="96 and 2mg/kg DPy doses, respectively" /><sentence text=" We used [(11)C]dLop PET imaging in baboons, a relevant in vivo model of P-gp function at the BBB, to show the P-gp inhibition potency of therapeutic dose CsA"><entity charOffset="155-157" id="DDI-PubMed.27283486.s31.e0" text="CsA" /></sentence><sentence text=" Despite in vitro P-gp inhibition potency, usual doses DPy are not likely to inhibit P-gp function at the BBB" /><sentence text=" " /></document>